<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31654">Gliclazide</z:chebi> is a sulphonylurea drug with an intermediate half-life of around 11 hours </plain></SENT>
<SENT sid="1" pm="."><plain>It is extensively metabolised, and renal clearance accounts for only 4% of total drug clearance </plain></SENT>
<SENT sid="2" pm="."><plain>The molecule contains an azabicyclo-<z:chebi fb="0" ids="25657">octyl group</z:chebi> which confers special properties on the basic sulphonylurea moiety </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="31654">Gliclazide</z:chebi> stimulates insulin secretion through the beta cell sulphonylurea receptor, and possibly through a direct effect on intracellular calcium transport </plain></SENT>
<SENT sid="4" pm="."><plain>It specifically improves the abnormal first phase insulin release in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and also has an effect on the second phase </plain></SENT>
<SENT sid="5" pm="."><plain>This pattern of insulin release is thought to explain the lower incidence of <z:e sem="disease" ids="C0745153" disease_type="Disease or Syndrome" abbrv="">hypoglycaemic episodes</z:e> and <z:mp ids='MP_0005456'>weight gain</z:mp> compared with some other sulphonylureas </plain></SENT>
<SENT sid="6" pm="."><plain>There is also a reduction in hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production and improvement in <z:chebi fb="105" ids="17234">glucose</z:chebi> clearance, without changes in insulin receptors </plain></SENT>
<SENT sid="7" pm="."><plain>This suggests a possible post-receptor effect on insulin action, perhaps by stimulation of hepatic <z:chebi fb="15" ids="28757">fructose</z:chebi>-2,6-bisphosphatase and muscle <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="31654">Gliclazide</z:chebi> reduces platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, aggregation and <z:hpo ids='HP_0000752'>hyperactivity</z:hpo> and increases fibrinolysis </plain></SENT>
<SENT sid="9" pm="."><plain>These actions, thought to be independent of its hypoglycaemic activity, may make <z:chebi fb="0" ids="31654">gliclazide</z:chebi> useful in halting the progression of <z:e sem="disease" ids="C0025945" disease_type="Disease or Syndrome" abbrv="">diabetic microangiopathy</z:e> </plain></SENT>
</text></document>